Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026)
Belite Bio (BLTE) posted quarterly Income from Continuing Operations of 26938000.0 for Q1 2026, down 88.68% year-over-year from 237991228.96 in Q1 2025, and up 99.89% quarter-over-quarter from 25324000000.0 in Q4 2025.
Powered by 
Analysis
Belite Bio (BLTE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Belite Bio's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 26938000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 88.68% year-over-year to 26938000.0; the TTM figure through Mar 2026 stood at 63360938000.0 (down 124.04% YoY), while the FY2025 annual figure was 77475000.0, down 131.85% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 26938000.0, up from 25324000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 6783000.0 in Q4 2022, with the low at 25324000000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 6853500000.0 (2023), against an average of 7377433062.5.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 144392.13% in 2024, then soared 99.82% in 2025.
- Belite Bio's Income from Continuing Operations stood at 6783000.0 in 2022, then dropped by 3.05% to 6990000.0 in 2023, then sank by 144392.13% to 10100000000.0 in 2024, then plunged by 150.73% to 25324000000.0 in 2025, then soared by 99.89% to 26938000.0 in 2026.
- Business Quant data shows BLTE's Income from Continuing Operations at 26938000.0 in Q1 2026, 25324000000.0 in Q4 2025, and 21690000000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Belite Bio | 6.26 Bn | 6.26 Bn | - | -28.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.41 Mn |
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -253.24 |
| Sep 30, 2025 | -21.69 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -101.00 |
| Sep 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -7.87 Mn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -68.12 |
| Mar 31, 2023 | -6.90 Mn |
| Dec 31, 2022 | -6.78 Mn |
| Jun 30, 2022 | -2.39 Mn |